📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-03 16:33
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
210 announcements match the current filters (relevance ≥ 5).
Board Approves ₹37.63 Cr Divestment of 17.96% Stake in Credo Advanced Chemicals
Gujarat Apollo Industries has approved in-principle the sale of its 17.96% stake (1.344 crore shares) in Credo Advanced Chemicals Limited to Mr. Naman Madhav Patel for a total cash consideration of ₹37.63 crore. The transaction size represents ~72.4% of the company's TTM revenue of ₹52 crore and ~9.9% of its market capitalization (₹379 crore). The sale is subject to shareholder approval at the upcoming 39th AGM scheduled for September 28, 2026, and is expected to close within 90 days of approval. Additionally, the Board fixed September 21, 2026, as the record date for dividend eligibility and AGM voting.
Confidence: HIGH
What changedGujarat Apollo entered an agreement to divest its entire 17.96% holding in Credo Advanced Chemicals for ₹37.63 crore in cash.
Why it mattersThe ₹37.63 crore cash realization significantly boosts liquidity and balance sheet strength for a company with ₹52 crore TTM revenue and ₹11 crore total debt.
Total sale consideration: ₹37,63,20,000Shares being sold: 1,34,40,000 Equity sharesEquity stake sold: 17.96%Consideration vs TTM revenue: ~72.4%Consideration vs Market cap: ~9.9%Target completion timeline: Within 90 days from shareholder approval
📅 Short termPositive sentiment driver ahead of the September 21, 2026 record date and the AGM vote on September 28, 2026.
📈 Long termUnlocks value from non-core investment holdings, bolstering the cash cushion to support diversification into construction and material handling equipment lines.
⚠ Risk flags
- Subject to shareholder approval under Regulation 37A of SEBI LODR.
- Execution risk regarding completion of payment and closing within the 90-day timeline.
Key Highlights
Approved sale of 1,34,40,000 shares (17.96% stake) in Credo Advanced Chemicals Limited for ₹37,63,20,000 (₹37.63 crore).
Divestment value equals ~72.4% of TTM revenue (₹52 crore) and ~14.1% of net worth (₹266 crore).
Credo Advanced Chemicals contributed 7.92% to total turnover and net worth in the previous financial year.
Sale is to a non-related party (Mr. Naman Madhav Patel) with completion expected within 90 days of shareholder approval.
Record date set for September 21, 2026, for dividend and the 39th AGM on September 28, 2026.
👀 What to Watch
Track the voting outcome of the AGM resolution on September 28, 2026, and monitor subsequent cash inflows and utilization plans across the 90-day completion timeline.
Apollo Pipes Seeks Approval for Non-Promoter Warrant Issue at ₹610/Warrant, Hikes Capital
Apollo Pipes Limited has issued a Postal Ballot notice seeking shareholder approval to raise its authorized share capital from ₹50 crore to ₹60 crore. Additionally, the company proposes a preferential issue of fully convertible warrants to eight non-promoter allottees at a price of ₹610 per warrant (against the regulatory minimum of ₹609.49). Remote e-voting commences on September 1, 2026, and ends on September 30, 2026, with the cut-off date set as August 28, 2026. The preferential capital raise will bolster liquidity to fund operational growth and capacity targets.
Confidence: HIGH
What changedThe company initiated a postal ballot to increase its authorized equity base to ₹60 crore and issue convertible warrants on a preferential basis to non-promoter entities.
Why it mattersProvides fresh equity funding to support ongoing capacity expansion (targeting 286,000 TPA) without increasing debt leverage.
Warrant Issue Price: ₹ 610 per warrantCurrent Market Price: ₹ 635.0Increase in Authorized Capital: ₹ 10 crore (1 crore shares)E-voting Conclusion Date: September 30, 2026
📅 Short termThe ₹610 issue price establishes a supportive equity valuation benchmark near the current market price of ₹635.
📈 Long termEquity infusion enhances balance sheet strength, enabling execution of high-margin product growth (CPVC/OPVC) and capacity scaling.
⚠ Risk flags
- Equity dilution for existing shareholders upon conversion of warrants into equity shares.
Key Highlights
Preferential issue of fully convertible warrants priced at ₹610 per warrant (minimum valuation floor ₹609.49).
Authorized share capital expanded from ₹50 crore (5 crore shares) to ₹60 crore (6 crore shares).
Eight non-promoter allottees named, including AGDG Enterprises LLP and Sukumar Srinivas.
Remote e-voting window open from September 1, 2026, to September 30, 2026.
👀 What to Watch
Track the final voting results post September 30, 2026, and company disclosures detailing the aggregate warrants issued and total capital raised.
Apollo Pipes to Raise ₹189.10 Cr via Warrants and Invest ₹300 Cr in Tiles & Ceramics Foray
Apollo Pipes' Board approved an investment plan of up to ₹300 crore to enter the tiles and ceramics business via new subsidiaries, including potential M&A of operating units. To fund growth, the company approved a preferential issue of up to 31,00,000 convertible warrants at ₹610 per warrant to non-promoter investors, aggregating ₹189.10 crore. Post-conversion over an 18-month tenure, the new warrants will represent 6.31% of the fully diluted equity base. The Board also approved expanding authorized share capital from ₹50 crore to ₹60 crore.
Confidence: HIGH
What changedApollo Pipes approved a strategic diversification into tiles and ceramics with an investment envelope of ₹300 crore and initiated an equity-linked fundraise of ₹189.10 crore via convertible warrants.
Why it mattersThe ₹300 crore capital deployment marks a significant diversification beyond plastic piping into adjacent building materials, while the ₹189.10 crore fundraise bolsters the balance sheet to finance capex/acquisitions.
Warrant fundraise amount: ₹189,10,00,000Warrant issue price: ₹610 per warrantWarrants offered: 31,00,000Tiles & ceramics investment plan: ₹300 croreInvestment vs TTM revenue: ~26.7%Post-issue warrant dilution: 6.31%
📅 Short termShareholders will vote on the warrant issuance and capital clause alteration; receipt of 25% upfront warrant subscription money will provide immediate liquidity.
📈 Long termEntering the tiles and ceramics market leverages the company's distribution network in building materials, though execution efficiency and profitability in a competitive ceramics market will dictate return on capital.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution and integration risks entering a new competitive business segment (tiles & ceramics)
- Equity dilution of 6.31% upon warrant conversion over the 18-month tenure
- Subject to shareholder and statutory approvals
Key Highlights
Approved investment plan of up to ₹300 crore (~26.7% of TTM revenue) to enter tiles and ceramics segment
Preferential issue of up to 31,00,000 convertible warrants at ₹610 each, raising up to ₹189.10 crore
Warrant issue represents a 6.31% fully diluted stake across 8 non-promoter investors
Authorized share capital increased from ₹50 crore to ₹60 crore (6 crore shares of ₹10 face value)
👀 What to Watch
Track shareholder approval via postal ballot/EGM for the preferential issue and subsequent announcements regarding incorporation or acquisitions in the tiles subsidiary.
Apollo Pipes approves ₹300 Cr tiles entry & ₹189.1 Cr preferential warrant issue
Apollo Pipes' Board has approved an investment plan of up to ₹300 crore to enter the tiles and ceramics business via a newly incorporated subsidiary, including potential acquisitions of profitable manufacturing units. To support growth and funding, the company also approved a preferential issue of up to 31,00,000 fully convertible warrants at ₹610 per warrant (aggregating to ₹189.10 crore) to non-promoter investors. The proposed warrants will represent a 6.31% equity dilution on a fully diluted basis upon conversion over an 18-month period.
Confidence: HIGH
What changedApollo Pipes is diversifying beyond PVC/CPVC pipes into tiles and ceramics with a ₹300 crore investment plan, funded partly via a ₹189.10 crore preferential warrant issue.
Why it mattersThe ₹300 crore planned outlay represents ~26.7% of TTM revenue (₹1,125 crore) and ~35.5% of net worth (₹845 crore), signaling a major strategic push into building materials.
Tiles & Ceramics Investment Plan: ₹300 croresInvestment vs TTM Revenue: ~26.7%Fundraise via Warrants: ₹189.10 croresWarrant Issue Price: ₹610Post-Conversion Equity Dilution: 6.31%
📅 Short termNear-term focus will be on shareholder voting on the warrant issuance and the terms of initial capital deployment into the subsidiary.
📈 Long termSuccessful entry into tiles could leverage the company's existing building materials distribution network, though entry into a competitive sector entails execution and integration risks.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution and market integration risks in a new and highly competitive tiles/ceramics sector
- Equity dilution of 6.31% upon warrant conversion within 18 months
Key Highlights
Board approved an investment plan of up to ₹300 crore into a new subsidiary for tiles and ceramics business.
Approved issuance of up to 31,00,000 convertible warrants at ₹610 each, raising up to ₹189.10 crore.
Preferential allotment to 8 non-promoter investors resulting in 6.31% post-conversion diluted equity holding.
Authorized share capital increased from ₹50.00 crore to ₹60.00 crore to accommodate conversion.
👀 What to Watch
Track shareholder approval via upcoming EGM/postal ballot and monitor detailed capital allocation timelines and execution milestones for the new tiles and ceramics subsidiary.
CARE Rates ₹1,880 Cr Bank Facilities of Apollo Micro Systems; Placed on Watch (RWD)
CAREedge Ratings has assigned credit ratings of 'CARE A- (RWD)' to Apollo Micro Systems' ₹1,530.00 Cr long-term bank facilities and 'CARE A2+ (RWD)' to ₹350.00 Cr short-term bank facilities. Total rated facilities stand at ₹1,880.00 Cr, which is ~184% of the company's TTM revenue of ₹1,022 Cr. Both facilities have been placed under 'Rating Watch with Developing Implications' (RWD) following CARE's communication dated August 26, 2026.
Confidence: HIGH
What changedCAREedge assigned ratings of CARE A- (RWD) and CARE A2+ (RWD) across ₹1,880 Cr bank lines.
Why it mattersEnables formal credit access for executing large-scale defense and electronics production contracts, though RWD status indicates key corporate events are being monitored by the rating agency.
Long-term bank facilities: ₹1,530.00 CrShort-term bank facilities: ₹350.00 CrTotal rated facilities: ₹1,880.00 CrRated facilities vs TTM revenue: ~184%Assigned Long-Term Rating: CARE A- (RWD)
📅 Short termInvestors will await clarity on the specific developing events prompting the rating watch.
📈 Long termSubstantial sanctioned bank lines provide the liquidity required to support unit expansions and serial manufacturing execution.
⚠ Risk flags
- Rating assigned under 'Rating Watch with Developing implications (RWD)'
- Potential debt expansion if ₹1,880 Cr limits are heavily drawn
Key Highlights
Long-term bank facilities of ₹1,530.00 Cr assigned rating of 'CARE A- (RWD)'
Short-term bank facilities of ₹350.00 Cr assigned rating of 'CARE A2+ (RWD)'
Aggregate rated bank facilities amount to ₹1,880.00 Cr
Total rated facility envelope represents ~184% of TTM revenue (₹1,022 Cr) and ~142% of Net Worth (₹1,323 Cr)
👀 What to Watch
Track the detailed rating rationale from CAREedge to understand the triggers behind the 'Rating Watch with Developing implications' and monitor subsequent resolution updates.
Apollo Micro Systems acquires 34% stake in new defence R&D entity Shauryastra Defence Systems
Apollo Micro Systems has incorporated an associate company, Shauryastra Defence Systems Private Limited, by subscribing to a 34% equity stake for Rs 34,000 (3,400 shares at Rs 10 each). The new entity was incorporated on August 21, 2026, and is led by Dr. V. K. Saraswat, former Director General of DRDO and Secretary of Defence R&D. The venture aims to design and develop complete weapon systems, long-range platforms, and unmanned systems, leveraging Apollo's existing manufacturing infrastructure to transition the company from a subsystem supplier to a complete weapon system developer.
Confidence: HIGH
What changedApollo Micro Systems has formed a dedicated 34%-owned associate entity (Shauryastra Defence Systems) to spearhead complete weapon system design and technology development.
Why it mattersMarks a strategic shift for Apollo from being a component and subsystem supplier (TTM revenue Rs 1,022 Cr) to a lead system integrator and complete platform developer.
Equity stake acquired: 34%Total subscription value: Rs. 34,000/-Number of shares subscribed: 3,400Date of incorporation: 21.08.2026
📅 Short termMinimal immediate financial impact given the nominal initial investment of Rs 34,000, though positive for market sentiment given the high-profile leadership.
📈 Long termIf successful in winning Development-cum-Production Partner (DcPP) or Make II programs, this could significantly expand Apollo's addressable defence market into prime contractorship.
⚠ Risk flags
- Long gestation and development cycles inherent in complex weapon systems R&D
- Dependence on DRDO/MoD qualification clearances and future capital calls for scaling R&D
Key Highlights
Subscribed to 3,400 equity shares of Rs 10 each, aggregating to an initial cash investment of Rs 34,000.
Holds a 34% paid-up equity stake in Shauryastra Defence Systems Private Limited (incorporated August 21, 2026).
Promoted and guided by Dr. V. K. Saraswat, former DG of DRDO and architect of India's missile programs.
Entity focuses on research, design, and development of complete weapon systems, long-range systems, and unmanned platforms.
👀 What to Watch
Track announcements regarding initial R&D project sanctions, Defence Ministry (Make II/iDEX) project awards, and capital allocation toward Shauryastra Defence Systems.
SEBI Directs Open Offer for 26% Stake in Premier Explosives at ₹698/Share Post-CCI Clearance
Apollo Micro Systems has received a directive from SEBI regarding its open offer to acquire up to 1,39,77,911 shares (26.00% stake) of Premier Explosives Limited at ₹698 per share. The open offer represents a total potential outlay of approximately ₹975.66 Cr, which is about 95.5% of Apollo's TTM revenue (₹1,022 Cr). SEBI has permitted the tendering period to begin within 12 working days of receiving Competition Commission of India (CCI) approval. Payments to tendering shareholders must be made within 10 working days of the tendering close, subject to a 10% per annum interest payout for any delay.
Confidence: HIGH
What changedSEBI issued clearance guidelines linking the commencement of the open offer tendering timeline directly to the receipt of CCI approval.
Why it mattersA successful 26% acquisition in Premier Explosives deepens Apollo's footprint in military and aerospace explosives, but requires significant funding (~₹975.66 Cr vs net worth of ₹1,323 Cr).
Shares to acquire: 1,39,77,911 shares (26.00%)Offer price per share: INR 698Total open offer value: ~₹975.66 CrOpen offer vs TTM revenue: ~95.5%Open offer vs Net worth: ~73.7%Delay interest rate: 10% per annum
📅 Short termMarket focus will shift to CCI review proceedings and funding structure disclosures for this sizeable transaction.
📈 Long termConsolidating or partnering with Premier Explosives can create vertical integration synergies in defense explosives and missile sub-systems.
⚠ Risk flags
- Regulatory risk: Transaction hinges on CCI approval.
- Funding/Leverage risk: Total deal size is close to ~74% of net worth, potentially impacting balance sheet leverage.
- Interest penalty: Obligation to pay 10% p.a. interest for delays.
Key Highlights
Open offer for up to 1,39,77,911 equity shares, representing 26.00% of Premier Explosives Limited
Offer price fixed at INR 698 per equity share of face value INR 2 each (aggregate value ~₹975.66 Cr)
Tendering window to commence not later than 12 working days following Competition Commission of India (CCI) approval
Acquirer required to pay interest at 10% per annum for the delay period on successful tenders
👀 What to Watch
Track the receipt of Competition Commission of India (CCI) approval and the subsequent announcement of the formal tendering window dates.
APL Apollo Sets Sep 8, 2026 Record Date for ₹8.50/Share Final Dividend
APL Apollo Tubes Limited has fixed Tuesday, September 8, 2026, as the record date for determining shareholder eligibility for its final dividend of ₹8.50 per equity share (face value ₹2) for FY26. The dividend is subject to shareholder approval at the upcoming 41st Annual General Meeting scheduled for September 15, 2026. The payout represents the distribution of FY26 earnings, in which the company posted a full-year net profit of ₹1,081.59 crore on revenue of ₹22,627.3 crore.
Confidence: HIGH
What changedAPL Apollo has formalized the record date (September 8, 2026) and AGM date (September 15, 2026) for the FY26 final dividend payout.
Why it mattersConfirms the timeline for cash returns to shareholders from FY26 profits, with dividend yield and total outflow being standard corporate cash return metrics.
Final Dividend per share: ₹8.50Face Value per share: ₹2Record Date: 08-Sep-2026AGM Date: 15-Sep-2026
📅 Short termStock will trade ex-dividend ahead of September 8, 2026, with typical price adjustment corresponding to the ₹8.50 per share payout.
📈 Long termLimited; this is a routine annual dividend distribution and does not alter the company's operating outlook or structural earnings growth trajectory.
Key Highlights
Record date fixed as September 8, 2026 for final dividend entitlement
Final dividend of ₹8.50 per equity share of face value ₹2 recommended for FY25-26
41st Annual General Meeting (AGM) scheduled for September 15, 2026 via VC/OAVM
Dividend recommended originally by the Board on May 2, 2026
👀 What to Watch
Investors seeking dividend eligibility must hold shares before the ex-dividend date preceding September 8, 2026. Watch for AGM voting outcomes and final dividend disbursement timelines.
Apollo Micro Systems Secures Orders Worth Rs 80.84 Cr (INR 808.38 Mn)
Apollo Micro Systems Limited has received new orders aggregate worth INR 808.38 million (~Rs 80.84 crore) in the ordinary course of business. The contracts were awarded across Defence PSUs, State Governments, and Private Industries. This order intake accounts for approximately 7.9% of the company's TTM revenue of Rs 1,022 crore. The win supports the company's ongoing revenue visibility across its defense electronics and systems business.
Confidence: HIGH
What changedApollo Micro Systems won new contracts totaling INR 808.38 million from defense PSUs, state governments, and private industry clients.
Why it mattersProvides near-term order book additions and revenue visibility, contributing approximately 7.9% relative to TTM revenue.
Total order value: INR 808.38 MillionsOrder value in ₹ Cr: ₹80.84 CrOrder vs TTM revenue: ~7.9%TTM revenue: Rs 1022 Cr
📅 Short termPositive for sentiment as it reflects continuous order conversion across defense and government segments.
📈 Long termSupports sustained top-line growth trajectory as the company scales manufacturing and leverages indigenous defense procurement.
⚠ Risk flags
- Execution and delivery timeline risks
- Raw material price volatility impacting gross margins
Key Highlights
Secured new orders worth INR 808.38 million (~Rs 80.84 crore)
Orders received from Defence PSUs, State Governments, and Private Industries
Order size represents ~7.9% of TTM revenue (Rs 1,022 crore)
Awarded in the ordinary course of business
👀 What to Watch
Track order execution timelines and monitor subsequent quarterly revenue realization and operating margins.
Apollo Micro Systems Receives SEBI Comments for 26% Open Offer in Premier Explosives
Apollo Micro Systems has received final comments from SEBI on August 16, 2026 (via letter dated August 14, 2026) regarding its Draft Letter of Offer to acquire up to 26% equity shares of Premier Explosives Limited (PEL). This follows the company's initial open offer announcement dated July 9, 2026. The clearance marks an essential regulatory step enabling the company to proceed with the final Letter of Offer and tendering schedule under SEBI SAST Regulations.
Confidence: HIGH
What changedSEBI cleared and issued its final comments on Apollo Micro Systems' Draft Letter of Offer for acquiring a 26% stake in Premier Explosives Limited.
Why it mattersClearing SEBI review enables Apollo to execute its open offer, progressing its strategic entry into defense and military explosives.
Open offer stake in PEL: 26%SEBI comment letter date: August 14, 2026Receipt date: August 16, 2026Initial announcement date: July 9, 2026
📅 Short termApollo Micro Systems will publish the final Letter of Offer and open the tendering window for PEL shareholders in the coming weeks.
📈 Long termStrengthens Apollo's footprint and vertical integration within the defense, missile programs, and energetics supply chain upon completion.
⚠ Risk flags
- Tender acceptance rate uncertainty
- Cash outflow and funding requirements for acquisition
- Post-transaction operational integration
Key Highlights
Received SEBI final comments on Draft Letter of Offer on August 16, 2026 (letter dated August 14, 2026)
Open offer involves the acquisition of up to 26% equity shares from public shareholders of Premier Explosives Limited
Advances transaction process initiated via earlier intimation on July 9, 2026
👀 What to Watch
Track the upcoming dispatch of the final Letter of Offer and the announcement of the official tendering schedule and financial outlay for the PEL open offer.
Gujarat Apollo Enters Road Construction Space; Sells Asphalt Plant & Paver Finisher
Gujarat Apollo Industries has officially commenced the manufacturing and sales of Road Construction Equipment. As part of this rollout, the company has manufactured and sold an Asphalt Mixing Plant and a Paver Finisher. This foray marks a strategic diversification beyond its traditional crushing and screening portfolio against a TTM revenue base of Rs 52 Cr. Specific unit volumes, pricing, and revenue contributions for these initial sales were not disclosed in the announcement.
Confidence: MEDIUM
What changedGujarat Apollo has begun commercial manufacturing and recorded its first sales of road construction equipment (Asphalt Mixing Plant and Paver Finisher).
Why it mattersExpands the company's addressable market into road construction infrastructure, providing a potential avenue to scale revenue above its current TTM base of Rs 52 Cr.
Products commercialized: Asphalt Mixing Plant and Paver FinisherSales value: not disclosedTTM Revenue: Rs 52 CrMarket Capitalization: Rs 372 Cr
📅 Short termValidates the company's product rollout timeline, though market impact may remain moderate until revenue contribution is quantified in quarterly reports.
📈 Long termCould structurally diversify the business if the company establishes significant market share in road construction machinery against domestic competitors.
⚠ Risk flags
- No financial details provided regarding sales value or margins
- Intense competitive pressure in road construction equipment may impact profitability
Key Highlights
Commenced commercial manufacturing and sales of Road Construction Equipment on August 14, 2026
Successfully manufactured and sold Asphalt Mixing Plant and Paver Finisher
Marks initial execution of stated strategy to expand beyond crushing and screening equipment
Specific order values and sales figures were not disclosed in the filing
👀 What to Watch
Track revenue and segment disclosures in subsequent quarterly results to assess commercial traction and margin impact from the road construction equipment division.
Gujarat Apollo Reappoints CMD Asit Patel for 3 Years; Forays into Road Construction Equipment
Gujarat Apollo Industries has approved the re-appointment of Mr. Asit A. Patel as Chairman cum Managing Director for a 3-year term starting September 1, 2026, subject to shareholder approval. The board also approved the appointment of Mr. Aryan A. Patel (holding 35,200 shares) as Manager-Technical/Executive-Business Development effective October 1, 2026. Concurrently, the company announced its operational entry into road construction equipment by completing manufacturing and sales of its first Asphalt Mixing Plant and Paver Finisher. Q1 financial results for the quarter ended June 30, 2026, were also adopted at the board meeting.
Confidence: HIGH
What changedRe-appointment of CMD for 3 years, addition of a next-generation promoter-family member to senior management, and initial sales of newly developed road construction machinery.
Why it mattersEnsures leadership continuity while bringing technical expertise into business development as the company attempts to diversify beyond its core crushing equipment to counter recent operating losses.
CMD re-appointment tenure: 3 yearsCMD tenure start date: 01.09.2026Aryan Patel shareholding: 35,200 Equity SharesAsit Patel shareholding: 5,000 Equity SharesSenior management joining date: 01.10.2026
📅 Short termNeutral trading impact expected as leadership continuity is maintained and the board outcome was procedural.
📈 Long termThe commercial traction of new road construction equipment will be critical in reviving operating profitability from negative margins (-22.9% TTM OPM).
⚠ Risk flags
- Related-party appointment holding a place of profit subject to shareholder approval
- No order book size or financial quantification provided for the new road equipment business
Key Highlights
Re-appointed Mr. Asit A. Patel as Chairman cum Managing Director for a period of 3 years effective September 1, 2026.
Appointed related-party Mr. Aryan A. Patel (holding 35,200 equity shares) to Senior Management effective October 1, 2026.
CMD Mr. Asit A. Patel holds 5,000 equity shares in the company.
Announced the commercial rollout and initial sales of Asphalt Mixing Plants and Paver Finishers in the road construction segment.
👀 What to Watch
Track shareholder voting on management appointments at the upcoming AGM and monitor subsequent quarterly disclosures to quantify revenue contributions from new road construction equipment sales.
Gujarat Apollo Q1 Consolidated Revenue Falls 10% YoY to ₹9.98 Cr; Standalone PAT at ₹0.38 Cr
Gujarat Apollo Industries reported its unaudited financial results for the quarter ended June 30, 2026. Consolidated revenue from operations declined 10.0% YoY to ₹9.98 Cr (₹997.56 Lakhs) from ₹11.08 Cr in the previous year's corresponding quarter and down 22.3% QoQ. On a standalone basis, revenue rose 11.8% YoY to ₹7.41 Cr (₹740.57 Lakhs) with a net profit of ₹0.38 Cr (₹37.81 Lakhs), though profitability remains heavily sustained by other income of ₹4.27 Cr offsetting core operating losses.
Confidence: HIGH
What changedGujarat Apollo published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Why it mattersTop-line scale remains modest at under ₹10 Cr quarterly on a consolidated basis, with bottom-line profitability remaining dependent on non-operating other income rather than manufacturing margins.
Consolidated Revenue (Q1): ₹9.98 CrStandalone Revenue (Q1): ₹7.41 CrStandalone Other Income: ₹4.27 CrStandalone PAT (Q1): ₹0.38 CrStandalone Basic EPS: ₹0.29
📅 Short termSubdued operational execution and dependence on treasury/other income are likely to keep sentiment neutral in the near term.
📈 Long termStructural revival depends on the company's ability to diversify away from legacy crushing equipment into broader construction and material handling equipment at sustainable operating margins.
⚠ Risk flags
- Negative core operating margins before other income
- Persistent competitive pricing pressures in core equipment lines
- Concentration of revenue in a narrow volume base
Key Highlights
Consolidated revenue from operations decreased 10.0% YoY to ₹9.98 Cr (₹997.56 Lakhs) vs ₹11.08 Cr in Q1 FY26
Standalone revenue from operations stood at ₹7.41 Cr (₹740.57 Lakhs), up 11.8% YoY from ₹6.62 Cr
Standalone PAT reached ₹0.38 Cr (₹37.81 Lakhs) vs ₹0.10 Cr (₹9.77 Lakhs) in the year-ago period
Standalone other income of ₹4.27 Cr (₹427.40 Lakhs) helped offset core standalone operating expenses of ₹11.22 Cr
👀 What to Watch
Monitor whether the company can achieve positive core operating profit (excluding other income) and track progress on product diversification into construction and material handling equipment.
Apollo Tyres Appoints Rajeev Kumar Sinha as Executive Director for 5-Year Term
Apollo Tyres has appointed Mr. Rajeev Kumar Sinha as a Whole-time Director (Executive Director) for a five-year term effective August 13, 2026. Mr. Sinha, who joined the company in April 2025, currently serves as the Chief Manufacturing & Sustainability Officer. With over 36 years of experience at firms like Cipla, PepsiCo, and Glenmark, his elevation to the board signals a focus on manufacturing excellence and sustainability. The appointment is subject to shareholder approval via postal ballot.
Confidence: HIGH
What changedMr. Rajeev Kumar Sinha has been elevated from his role as Chief Manufacturing & Sustainability Officer to a seat on the Board of Directors as a Whole-time Director.
Why it mattersElevating the head of manufacturing to the board is significant for a capital-intensive tyre manufacturer with Rs 28,471 Cr in TTM revenue, as it ensures operational and sustainability strategies are represented at the highest decision-making level.
Term of Appointment: 5 yearsProfessional Experience: 36+ yearsTTM Revenue: Rs 28,471 CrMarket Capitalization: Rs 28,052 Cr
📅 Short termThe announcement is likely to have a neutral impact on the stock price in the short term as it represents a planned leadership transition.
📈 Long termThe appointment could strengthen the company's focus on manufacturing optimization and ESG goals, which are critical for maintaining its 14.6% OPM and global competitiveness.
Key Highlights
Appointment of Mr. Rajeev Kumar Sinha as Whole-time Director for a 5-year tenure starting August 13, 2026
Mr. Sinha brings over 36 years of experience across industries including pharma and FMCG
He joined Apollo Tyres on April 2, 2025, as Chief Manufacturing Officer
The board meeting for this approval was conducted in 25 minutes (2:30 PM to 2:55 PM)
Appointment is subject to shareholder approval through a Postal Ballot process
👀 What to Watch
Investors should monitor the results of the upcoming postal ballot for shareholder approval and watch for any shifts in manufacturing efficiency or sustainability metrics in future quarterly reports.
Apollo Tyres Appoints Rajeev Kumar Sinha as Whole-time Director for 5 Years
Apollo Tyres has elevated Mr. Rajeev Kumar Sinha, currently the Chief Manufacturing & Sustainability Officer, to the Board as a Whole-time Director for a five-year term starting August 13, 2026. Mr. Sinha, an IIT Kanpur alumnus, joined the company in April 2025 and brings over 36 years of experience from major firms like Cipla and PepsiCo. This appointment, subject to shareholder approval, places a direct focus on global manufacturing strategy and sustainability at the board level. The company currently operates six plants globally and reported a TTM revenue of Rs 28,471 Cr.
Confidence: HIGH
What changedMr. Rajeev Kumar Sinha has been promoted from Chief Manufacturing & Sustainability Officer to a Whole-time Director on the Board of Apollo Tyres.
Why it mattersElevating the manufacturing head to the board level signals a strategic priority on operational excellence and sustainability, which are critical for maintaining margins (currently 14.6% OPM) and managing the company's global manufacturing footprint.
Term of Appointment: 5 yearsProfessional Experience: 36+ yearsEffective Date: August 13, 2026TTM Revenue: Rs 28,471 Cr
📅 Short termThe announcement is administrative in nature and is unlikely to cause significant short-term stock price volatility.
📈 Long termStrengthening the board with a manufacturing and sustainability expert supports the company's long-term goals of premiumization and capacity optimization at its Indian and Hungarian plants.
Key Highlights
Appointment of Mr. Rajeev Kumar Sinha as Whole-time Director for a 5-year term effective August 13, 2026.
Mr. Sinha possesses over 36 years of leadership experience across Cipla, Glenmark, PepsiCo, and Cadbury.
He joined Apollo Tyres on April 2, 2025, and currently leads global manufacturing and sustainability agendas.
The appointment is subject to approval by shareholders through a Postal Ballot process.
The Board meeting was concise, commencing at 2:30 PM and concluding at 2:55 PM.
👀 What to Watch
Investors should monitor the upcoming Postal Ballot results for shareholder approval and look for any strategic shifts in manufacturing efficiency or sustainability targets in future quarterly updates.
Apollo Hospitals Targets ₹25,000 Cr HealthCo Revenue Run Rate by Q4 FY27
Apollo Hospitals (AHEL) has provided a strategic update on its HealthCo and Keimed merger, reporting a combined proforma revenue of ₹5,346.8 Cr for Q1 FY27. The company is targeting a massive annualized revenue run rate of ₹25,000 Cr for this integrated entity by Q4 FY27, with expected EBITDA margins of 6.5-7.0%. AHEL expects to list the 'New Co' (HealthCo) by Q4 FY27, maintaining a 59.2% majority stake. Digital 24/7 operating costs for the quarter stood at ₹81.1 Cr as the segment moves toward profitability.
Confidence: HIGH
What changedThe company has formalized the listing timeline for its integrated pharmacy and digital business (HealthCo) for Q4 FY27 and set a clear ₹25,000 Cr revenue run-rate target.
Why it mattersThe consolidation and listing of HealthCo simplify the corporate structure and create a massive integrated healthcare platform, potentially leading to a valuation re-rating of the parent company.
Combined Q1 Revenue: ₹5,346.8 CrTarget Annualized Revenue (Q4 FY27): ₹25,000 CrAHEL Stake in New Co: 59.2%Digital 24/7 Op Cost (Q1): ₹81.1 CrTarget EBITDA Margin: 6.5% - 7.0%
📅 Short termThe market is likely to view the clarity on the listing timeline and aggressive revenue targets for the pharmacy business as a positive development.
📈 Long termThe successful integration of Keimed and the listing of HealthCo represent a structural shift toward a dominant omni-channel healthcare player in India.
⚠ Risk flags
- Regulatory approval delays for the merger
- Execution risk in achieving the ₹25,000 Cr run rate
- Continued cash burn in digital operations
Key Highlights
Combined proforma revenue for HealthCo and Keimed reached ₹5,346.8 Cr in Q1 FY27
Targeting an annualized revenue run rate of ₹25,000 Cr for the integrated entity by Q4 FY27
Estimated listing of the merged 'New Co' scheduled for Q4 FY27 post-regulatory approvals
AHEL to retain a 59.2% stake in the combined entity following the Keimed amalgamation
Digital 24/7 operating costs (excluding ESOP) were ₹81.1 Cr for the June 2026 quarter
👀 What to Watch
Monitor the NCLT and shareholder approval process for the Keimed merger and the specific listing timeline in Q4 FY27, which serves as a major value-unlocking catalyst.
Apollo Hospitals Targets Rs 25,000 Cr HealthCo Revenue Run Rate by Q4 FY27
Apollo Hospitals (AHEL) reported its Q1 FY27 investor update, highlighting a proforma combined revenue of Rs 5,346.8 Cr for its HealthCo and Keimed segments. The company is on track for the composite scheme to merge Keimed into Apollo HealthCo, with an estimated listing of the new entity by Q4 FY27. Management has set a target annualized revenue run rate of Rs 25,000 Cr for the new entity by Q4 FY27, with EBITDA margins expected between 6.5% and 7.0%. The core hospital segment continues its aggressive expansion, targeting 4,300 additional beds across 15 new hospitals.
Confidence: HIGH
What changedThe company provided a concrete timeline for the listing of its pharmacy and digital business (Q4 FY27) and specific financial targets for the merged entity.
Why it mattersThe reorganization simplifies the corporate structure, consolidates the pharmacy supply chain, and provides a clear path to profitability for the digital segment, which has been a drag on margins.
New Co Q1 Revenue: Rs 5,346.8 CrTarget Revenue Run Rate: Rs 25,000 CrAHEL Stake in New Co: 59.2%Planned Bed Addition: 4,300 unitsDigital Platform Users: 44 million
📅 Short termThe stock may see positive sentiment due to the clarity on the HealthCo listing timeline and the narrowing of digital losses.
📈 Long termThe addition of 4,300 beds (approx. 40% increase over current capacity) and the scaling of the omni-channel pharmacy business are structural growth drivers for the next 3-4 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in Keimed merger
- Regulatory pricing pressure on pharmacy margins
- Continued cash burn in digital therapeutics
Key Highlights
Targeting Rs 25,000 Cr annualized revenue run rate for the new HealthCo entity by Q4 FY27
Q1 FY27 combined EBITDA for HealthCo and Keimed reached Rs 389.8 Cr at a 7.3% margin
Apollo 24/7 digital platform operating costs stood at Rs 81.1 Cr for the quarter
Planned expansion of 4,300 beds across 15 new hospitals in Metro Tier 1 and Tier 2 cities
AHEL to retain a 59.2% controlling stake in the new entity post-merger and listing
👀 What to Watch
Investors should monitor the regulatory and NCLT approval progress for the Keimed merger and the subsequent listing of Apollo HealthCo, which is a key value-unlocking event.
Apollo Hospitals Q1 Standalone PAT up 25.5% to ₹385 Cr; FMCG Slump Sale Approved
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue growing 22.5% YoY to ₹2,656.1 Cr. Standalone PAT rose 25.5% to ₹385.2 Cr, driven by a 20.2% increase in EBITDA to ₹656.2 Cr. The board also approved a slump sale of the FMCG and wellness distribution business from its material subsidiary, Apollo Healthco, to a new wholly-owned subsidiary, Apollo Consumer Products Ltd. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting in 2027.
Confidence: HIGH
What changedApollo reported its Q1 FY27 standalone results and initiated a corporate restructuring to move its FMCG distribution business into a dedicated subsidiary.
Why it mattersThe strong standalone growth reflects robust hospital operations, while the slump sale of the FMCG unit indicates a strategic move to streamline the retail and distribution business structure.
Standalone Revenue (Q1 FY27): ₹2,656.1 CrStandalone PAT (Q1 FY27): ₹385.2 CrStandalone EBITDA: ₹656.2 CrQ1 Standalone Revenue vs TTM Revenue: 10.53%ESOP Grant (Shares): 46,798
📅 Short termThe stock is likely to react positively to the double-digit growth in standalone revenue and profitability.
📈 Long termThe company's focus on high-end surgical cases, pharmacy expansion, and narrowing digital platform losses supports a positive long-term outlook.
⚠ Risk flags
- Regulatory changes in healthcare pricing
- Continued cash burn in the Apollo 24/7 digital platform
Key Highlights
Standalone Revenue from operations increased 22.5% YoY to ₹2,656.1 Cr in Q1 FY27
Standalone Profit After Tax (PAT) grew 25.5% YoY to ₹385.2 Cr from ₹306.9 Cr
Standalone EBITDA reached ₹656.2 Cr, up 20.2% compared to ₹546.1 Cr in Q1 FY26
Approved slump sale of FMCG and wellness undertaking from Apollo Healthco Ltd to Apollo Consumer Products Ltd
Granted 46,798 additional stock options and RSUs to new employees under the 2024 ESOP plan
👀 What to Watch
Investors should monitor the consolidated results to assess the impact of Apollo 24/7's narrowing losses and the execution of the planned 4,300-bed capacity expansion.
25.5% PAT Growth: Apollo Hospitals Reports Q1 FY27 Standalone Revenue of ₹2,656 Cr
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue from operations reaching ₹2,656.1 Cr, a 22.5% increase from ₹2,167.9 Cr in Q1 FY26. Standalone Profit After Tax (PAT) grew 25.5% YoY to ₹385.2 Cr, while EBITDA rose 20.2% to ₹656.2 Cr. The company also announced a strategic slump sale of its FMCG and wellness undertaking from its subsidiary Apollo Healthco to a new wholly-owned subsidiary, Apollo Consumer Products Limited. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting in 2027.
Confidence: HIGH
What changedApollo Hospitals reported its Q1 FY27 standalone financial results, initiated a corporate restructuring of its FMCG business, and appointed new statutory auditors for a future term.
Why it mattersThe strong standalone growth reflects robust demand in hospital services and improved operational efficiency. The slump sale of the FMCG business suggests a strategic move to streamline consumer-facing operations for better focus or potential monetization.
Standalone Revenue (Q1 FY27): ₹2,656.1 CrStandalone PAT (Q1 FY27): ₹385.2 CrEBITDA (Q1 FY27): ₹656.2 CrYoY Revenue Growth: 22.5%YoY PAT Growth: 25.5%ESOP Grant: 46,798 shares
📅 Short termThe stock may react positively to the double-digit growth in standalone revenue and profitability, which exceeded the previous year's performance.
📈 Long termThe company's focus on high-end surgical mix, bed expansion, and the narrowing losses in the digital segment support a positive structural outlook over the next few years.
⚠ Risk flags
- Regulatory changes in healthcare pricing
- Execution risk of the 4,300-bed expansion
- Continued cash burn in the digital platform (Apollo 24/7)
Key Highlights
Standalone revenue from operations grew 22.5% YoY to ₹2,656.1 Cr in Q1 FY27
Standalone PAT increased to ₹385.2 Cr compared to ₹306.9 Cr in the previous year's corresponding quarter
EBITDA for the quarter stood at ₹656.2 Cr, up from ₹546.1 Cr in Q1 FY26
Board approved the grant of 46,798 additional stock options under the Apollo ESOP Plan 2024
Subsidiary Apollo Healthco to transfer its FMCG/wellness business to Apollo Consumer Products via a slump sale
👀 What to Watch
Investors should monitor the consolidated results to assess the performance of the Apollo 24/7 digital platform and the impact of the FMCG business restructuring. The execution of the planned 4,300-bed expansion remains a key long-term growth driver.
Apollo Hospitals Q1 Standalone PAT Rises 25.5% YoY to ₹385 Cr; Subsidiary Slump Sale Approved
Apollo Hospitals reported a strong standalone performance for Q1 FY27, with revenue growing 22.5% YoY to ₹2,656.1 Cr. Standalone PAT increased 25.5% YoY to ₹385.2 Cr, while EBITDA rose 20.2% to ₹656.2 Cr. The company also announced a structural change where its material subsidiary, Apollo Healthco (AHL), will transfer its FMCG wholesale distribution business to a new wholly-owned subsidiary, ACPL, via a slump sale. Additionally, Price Waterhouse was appointed as the statutory auditor for a five-year term starting from the 2027 AGM.
Confidence: HIGH
What changedApollo Hospitals reported double-digit growth in its standalone Q1 FY27 results and initiated a corporate restructuring of its pharmacy/FMCG distribution business within its subsidiary Apollo Healthco.
Why it mattersThe strong standalone growth confirms the robust demand in core hospital services and improved surgical mix. The slump sale in the subsidiary suggests a strategic move to isolate the FMCG wholesale business, potentially for operational efficiency or future monetization.
Standalone Revenue (Q1 FY27): ₹2,656.1 CrStandalone PAT (Q1 FY27): ₹385.2 CrYoY Revenue Growth: 22.5%YoY PAT Growth: 25.5%EBITDA: ₹656.2 CrESOP Grant (Shares): 46,798 units
📅 Short termThe stock is likely to react positively to the 25%+ growth in standalone PAT and steady EBITDA margins, reflecting strong operational performance in the core hospital segment.
📈 Long termThe company's structural growth is supported by its massive bed expansion plan and the scaling of the Apollo 24/7 platform. The consolidation of pharmacy operations and the entry into electric air ambulances indicate a focus on high-tech healthcare leadership.
⚠ Risk flags
- Continued cash burn in the Apollo 24/7 digital platform
- Regulatory risks regarding healthcare pricing and medicine tariffs
- Dependency on Keimed for pharmacy distribution
Key Highlights
Standalone revenue from operations reached ₹2,656.1 Cr in Q1 FY27, up from ₹2,167.9 Cr in Q1 FY26.
Standalone Profit After Tax (PAT) grew to ₹385.2 Cr, representing a 25.5% increase over the same period last year.
EBITDA for the quarter stood at ₹656.2 Cr, a 20.2% growth compared to ₹546.1 Cr in Q1 FY26.
Apollo Healthco Limited to transfer its FMCG and wellness wholesale distribution undertaking to Apollo Consumer Products Limited (ACPL).
Board approved the grant of 46,798 additional stock options/RSUs to new employees under the ESOP 2024 plan.
👀 What to Watch
Investors should monitor the consolidated results to assess the impact of Apollo 24/7's digital platform losses on overall profitability. The execution of the planned 3,500-4,300 bed expansion and the streamlining of the pharmacy distribution business via the AHL slump sale are key long-term value drivers to watch.
